Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 14th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 14th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

March 1st 2017

Kite Pharma Reports Positive Data From ZUMA-1, Evaluating a CAR-T Treatment

AJMC Staff

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

February 28th 2017

Smilow's In-House Pharmacy Saved Costs, Beneficial to Patients

Surabhi Dangi-Garimella, PhD

Expanding a health system pharmacy’s operations to include specialty drugs, namely oral oncology agents, improved patient care by reducing errors and saving costs.

February 27th 2017

NCI-Funded Study Hopes to Unveil Disparity Among African American Cancer Survivors

Surabhi Dangi-Garimella, PhD

A new grant aims to gather data on thousands of African American cancer survivors to understand factors that influence disease progression, recurrence, mortality, and quality of life.

February 27th 2017

Proposed Colorectal Cancer Screening Initiatives Vary in Cost-Effectiveness

Christina Mattina

A recent cost-effectiveness analysis of 4 colorectal cancer screening initiatives found that some strategies may be more valuable than others in reducing screening disparities.

February 26th 2017

Jonathan Hirsch: Precision Medicine Is the Future of Value-Based Cancer Care

Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.

February 24th 2017

Personalizing Cancer Treatment Based on Muscle Mass to Reduce Toxicity

Surabhi Dangi-Garimella, PhD

Using body composition metrics to guide the dose in patients receiving anthracyclines-taxane—based chemotherapy for breast cancer can reduce treatment-related toxicity.

February 23rd 2017

Podcast: Takeaways From the 5th Annual Patient-Centered Oncology Care Meeting

Presenters and panelists at the 5th annual Patient-Centered Oncology Care meeting provide their key takeaways.

February 23rd 2017

Lenalidomide Approved as Maintenance for Multiple Myeloma Following Transplant

AJMC Staff

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.

February 23rd 2017

Dr Joseph Alvarnas Discusses Awareness of Cancer Patients' Financial Concerns

Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology, admits that he was once “oblivious” to his patients’ concerns about the cost of cancer treatment. However, it is important for clinicians to empathize with these fears and understand how they can factor into a patient’s care choices.

February 23rd 2017

AJMC®'s Evidence-Based Oncologyâ„¢ Publishes Third Annual Immuno-Oncology Issue

The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncologyâ„¢, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.

February 22nd 2017

Bundled Payments and Other Cost-Management Approaches to Oncology Care

Christina Mattina

At the 5th annual Patient-Centered Oncology CareÂ® meeting, stakeholders shared their views on how bundled payments, clinical pathways, and other value-based approaches can be implemented in cancer care while ensuring adequate care quality.

February 22nd 2017

Panel Presents Unique Cost-Sharing Viewpoints in Oncology Care

Christina Mattina

Panelists from diverse vantage points in the cancer care landscape discussed the effects of cost sharing on patients in a discussion at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 22nd 2017

Integrating Patient-Centered Outcomes in APMs

Surabhi Dangi-Garimella, PhD

As payment models shift to emphasize patient experience and quality of care, a panel discussion at the 5th annual Patient-Centered Oncology CareÂ® meeting debated whether these efforts had meaningfully improved outcomes for patients.

February 22nd 2017

CVS Decision to Stop Tobacco Sales Reduced Cigarette Purchase

Surabhi Dangi-Garimella, PhD

The company's study has found a 38% drop in cigarette purchase among shoppers who visit CVS stores.

February 22nd 2017

Exercise Most Powerful Lifestyle Factor in Improving Breast Cancer Outcomes

Christina Mattina

A recent literature review, examining evidence on lifestyle changes that can reduce the risk of recurrence or death for women diagnosed with breast cancer, found that exercise can reduce the risk of both outcomes.

February 22nd 2017

Samantha Watson Describes How Cancer Patients Balance Health With Finances

As founder and CEO of The Samfund, Samantha Watson has found that most cancer patients prioritize their physical health over their financial stability, leaving them lagging behind their peers economically or even facing bankruptcy.

February 21st 2017

Age, Plan Deductible Influence Prescription Changes Among Cancer Survivors

AJMC Staff

Researchers at the American Cancer Society have found that nonelderly cancer survivors enrolled in high-deductible health plans are more likely to seek a change to a lower-cost prescription medication compared with those without a cancer history.

February 21st 2017

Specialty Pharmacies Transforming Cancer Care

Surabhi Dangi-Garimella, PhD

Specialty pharmacies can collaborate with clinical teams to harness the power of health information technology and improve cancer care, according to panelists at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 21st 2017

Cholesterol-Lowering Medications Complement Endocrine Therapy in Breast Cancer

Surabhi Dangi-Garimella, PhD

Including anti-cholesterol agents during adjuvant endocrine treatment can prevent breast cancer recurrence in hormone receptor—positive early-stage breast cancer.

February 20th 2017

TAPUR Trial Expands Who Can Join Clinical Trials, If Payers Fund Genomic Tests

Mary Caffrey

Pam Mangat, MS, associate director for the TAPUR study in the research and analysis division of the American Society of Clinical Oncology, offered an update on the study at the 5th annual Patient-Centered Oncology CareÂ® meeting.

February 20th 2017

Developments in Immunotherapy at PCOC®: The Living Drugs

Surabhi Dangi-Garimella, PhD

David L. Porter, MD, kicked off the 5th annual Patient-Centered Oncology CareÂ® (PCOCÂ®) meeting in Baltimore on November 17, 2016, with an update on chimeric antigen receptor T-cell therapy.

February 20th 2017

Responding to Patient Needs Central to Providing Value in Cancer Care

Christina Mattina

At the 5th annual Patient-Centered Oncology CareÂ® meeting, Nell Wood Buhlman of Press Ganey explained that oncology providers must focus on patient needs and minimize suffering in order to truly provide value in cancer care.

February 20th 2017

Immunoâ€Oncology Versus Precision Medicine: Where Is Cancer Care Headed?

Surabhi Dangi-Garimella, PhD

At the 5th annual Patient-Centered Oncology CareÂ® meeting, hosted by The American Journal of Managed CareÂ®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.

February 20th 2017

The Future of Oncology Care: 2017 and Beyond

Christina Mattina

Bruce A. Feinberg, DO, moderated a panel at the 5th annual Patient-Centered Oncology CareÂ® meeting that brought stakeholders together to share their cancer care predictions for the upcoming year.

February 20th 2017

Cancer Trial Participants Can Successfully Self-Report Adverse Events

Christina Mattina

Adverse events from cancer clinical trials are currently reported by trial investigators, but a recent feasibility study found that patients can successfully and accurately report their own symptoms if given the opportunity.

February 19th 2017

OlympiAD Trial Reports Success With Olaparib and Predictive Diagnostic Test

Surabhi Dangi-Garimella, PhD

The trial successfully improved progression-free survival and also tested a BRCA diagnostic test in patients with ovarian cancer.

February 19th 2017

Dr Carrie Stricker on How Carevive Integrates Patient-Reported Outcomes Into Care Planning

Carevive recognizes the importance of including patient-reported outcomes into the care planning process, so they have developed surveys that will provide patients with the resources to address those concerns, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

February 17th 2017

Pharma—PBM War on Drug Prices Picks Up Steam

Surabhi Dangi-Garimella, PhD

An e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association, to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.

February 17th 2017

This Week in Managed Care: February 17, 2017

This week, the top managed care stories included the end of 2 insurance megamergers, a proposed rule to tighten restrictions for the Affordable Care Act, and new legislation in New Jersey provides the nation's strictest mandates for treating addiction.

February 17th 2017

Pam Mangat on the Future of Surrogate Endpoints and Genetic Sequencing in Cancer Care

Surrogate endpoints could eventually add to or replace clinical endpoints in determining a cancer treatment’s effectiveness, according to Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology. She also said that a deeper understanding of a patient’s genetic makeup and tumor biology in conjunction with new technologies will drive improvements in oncology care.

...

82 83 84 85 86 87 88 89 90

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions